Full Text View
Tabular View
No Study Results Posted
Related Studies
Reversal of Ventricular Remodeling With Toprol-XL
This study has been completed.
Study NCT00038077   Information provided by AstraZeneca
First Received: May 28, 2002   Last Updated: June 10, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Heart Failure, Congestive
Additional conditions recognized in this trial
Heart Failure
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Interventions listed in this trial
Toprol-XL 50 mg
Toprol-XL 200 mg
Placebo
Additional drug interventions recognized in this trial
Metoprolol
Metoprolol succinate
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sympatholytics
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services